提升血友病A小鼠体内血小板靶向基因治疗疗效
本研究在血友病A小鼠中通过地塞米松与抗CD8α单抗联合用药提高慢病毒转导效率,并采用功能增强型FVIII变体F8/N6K12RH,经骨内输注实现显著表型纠正且未产生抗FVIII抑制物。
要点
- 地塞米松联合抗CD8α单抗可提高骨髓及造血干细胞慢病毒转导比例。
- G-F8X10K12-LV虽提高血小板FVIII水平但诱导抗FVIII抑制物。
- 联合免疫抑制与G-F8/N6K12RH-LV骨内输注实现无抑制物的表型纠正。
核心结论
- 新FVIII变体F8/N6K12RH联合免疫抑制可显著增强骨内递送的血小板靶向基因治疗对小鼠血友病A的疗效。
研究设计与样本
- 在血友病A小鼠中开展骨内输注携带血小板特异性启动子驱动的FVIII转基因慢病毒载体的治疗研究。
主要发现
- 地塞米松与抗CD8α单抗联合用药随时间提高转导的骨髓及造血干细胞百分比。
- G-F8/N6-LV治疗的HemA小鼠在第84天观察到表型纠正显著改善。
- G-F8X10K12-LV治疗产生更高水平血小板FVIII但诱导抗FVIII抑制物。
- 联合药物与G-F8/N6K12RH-LV骨内输注后HemA小鼠表型显著纠正且无抗FVIII抑制物形成。
临床怎么用
- 该方案可能安全有效治疗血友病,尤其可能使存在FVIII抑制性抗体的患者获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our previous studies demonstrated that intraosseous (IO) infusion of lentiviral vectors (LVs) carrying a modified B domain-deleted factor VIII (FVIII) transgene driven by a megakaryocyte-specific promoter (GP1Bα promoter; G-F8/N6-LV) successfully transduced hematopoietic stem cells (HSCs) to produce FVIII stored in the platelet α-granules. Platelet FVIII corrected the bleeding phenotype with limited efficacy in hemophilia A (HemA) mice with and without preexisting anti-FVIII inhibitors. The present study sought to further enhance the therapeutic efficacy of this treatment protocol by increasing both the efficiency of LV transduction and the functional activity of platelet FVIII. A combined drug regimen of dexamethasone and anti-CD8α monoclonal antibody enhanced the percentage of transduced bone marrow and HSCs over time. In G-F8/N6-LV-treated HemA mice, significant improvement in phenotypic correction was observed on day 84. To improve platelet FVIII functionality, genes encoding FVIII variant F8X10K12 with increased expression or F8N6K12RH with increased functional activity compared with F8/N6 were incorporated into LVs. Treatment with G-F8X10K12-LV in HemA mice produced a higher level of platelet FVIII but induced anti-FVIII inhibitors. After treatment with combined drugs and IO infusion of G-F8/N6K12RH-LV, HemA mice showed significant phenotypic correction without anti-FVIII inhibitor formation. These results indicate that new human FVIII variant F8/N6K12RH combined with immune suppression could significantly enhance the therapeutic efficacy of in vivo platelet-targeted gene therapy for murine HemA via IO delivery. This protocol provides a safe and effective treatment for hemophilia that may be translatable to and particularly beneficial for patients with preexisting inhibitory antibodies to FVIII.
引用
- Wang X, Fu RY, Li C, et al. Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice. Blood Adv. 2020. PMID: 33216891. doi:10.1182/bloodadvances.2020002479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。